大分割三维适形放疗联合化疗治疗中晚期肝癌45例疗效分析

Three Dimensional Conformal Radiotherapy Combined with Concurrent Chemotherapy for Postoperative Thoracic Lymph Nodes Recurrence of Esophageal Cancer

目的探讨大分割三维适形放射治疗联合化疗治疗中晚期肝癌的疗效。方法对45例不能手术的中晚期肝癌患者进行介入治疗两次,其中22例结合大分割三维适形放射治疗,采用6MV X线,单剂量为3～5Gy,隔日1次,总剂量为DT45～55Gy23例单纯介入治疗。结果大分割三维适形放疗联合介入治疗组近期有效率(CR+PR)为85.7%,对照组为52.3%,两组差异有统计学意义;1、2、3年的生存率联合治疗组为68.7%,56.8%,39.8%,对照组为51.2%,28.7%,15.7%,两者差异有统计学意义。两组间不良反应差异无统计学意义(P>0.05)。结论对于不能手术切除的中晚期肝癌患者,大分割3DCRT结合TACE有较好的疗效,不良反应可以耐受。

Objective To analysis the effect of hyperfractionated three-dimensional eonformal radiotherapy （HF-3DCRT） combined with transarterial chemoembolization （TACE） for advanced liver carcinoma. Methods Total of 45 patients with unresectable advanced liver carcinoma were randomly devided into two groups： 22 patients were treated with HF-3DCRT plus TACE and the rest 23 patients were treated with TACE alone. TACE were treated with 2 sessions in either group. For HF-3DCRT, radiation was provided by 6MV X ray, patients received a total dose of 45-55Gy（3-5Gy per session） every other day. Results The survival rates of HF-3DCRT plus TACE group in the 1st, 2ed and 3rd year were 68. 7%, 56. 8%and 39. 8%; 51.2%, 28. 7% and 15.7%, respectively, in the TACE group. The differ- ence between the two groups was significant. The response rates （CR ＋ PR） of HF-3DCRT plus TACE group and TACE alone group were 85.7% and 52. 3%, the difference was statistically significant differ- ence. There was no difference of side-effect between the two groups （P〉0. 05）. Conclusion Hyperfrac tionated three-dimensional conformal radiotherapy plus transarterial chemoembolizaton is effective for the treatment of advanced liver carcinoma and the patients can tolerate the side-effects.